Nanologica AB (publ) announces that the company’s shares are admitted for trading on Nasdaq Stockholm’s main market today.
“Nanologica is about to launch a world-class product within chromatography that can cut costs for insulin manufacturers, which may enable treatment for more diabetes patients. At the same time, we are progressing our unique platform for local delivery of drugs to the lung through internal development, with the goal of giving patients with severe lung diseases access to new or improved treatments. With a highly qualified team and large-scale production soon in place, we are now ready to step up the business to completely new levels.Today’s listing on Nasdaq Stockholm gives Nanologica increased exposure and the opportunity to attract institutional and international investors to a greater extent”, Nanologica’s CEO Andreas Bhagwani comments.
“We are happy to welcome Nanologica as they join Nasdaq as a Main Market listed company,” says Adam Kostyál, Head of European Listings at Nasdaq. “They make a great contribution to society by making their vital products more accessible to customers and to the market. This will attract both investors and new shareholders. We look forward to follow their journey as a Main Market listed company.”
The shares will be traded on the Nasdaq Stockholm main market under the same ticker (NICA) and ISIN-code (SE0005454873). There is no offering or new share issue in connection with the list change, and shareholders in Nanologica do not need to take any actions.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed on Nasdaq Stockholm since March 29, 2022. For further information, please visit www.nanologica.com.